Amgen, Inc. (NASDAQ:AMGN) had its price objective boosted by Goldman Sachs from $213.00 to $218.00 in a research note released on Friday morning, StockTargetPrices.com reports.

Several institutional investors have recently bought and sold shares of AMGN. Park National boosted its position in Amgen by 0.9% in the fourth quarter. Park National now owns 13,303 shares of the medical research company’s stock valued at $2,159,000 after buying an additional 121 shares in the last quarter. EisnerAmper Wealth Management boosted its position in Amgen by 9.2% in the fourth quarter. EisnerAmper Wealth Management now owns 3,174 shares of the medical research company’s stock valued at $515,000 after buying an additional 267 shares in the last quarter. Renaissance Investment Group purchased a new position in Amgen during the fourth quarter valued at about $242,000. EQIS Capital Management boosted its position in Amgen by 580.0% in the fourth quarter. EQIS Capital Management now owns 21,352 shares of the medical research company’s stock valued at $3,466,000 after buying an additional 18,212 shares in the last quarter. Finally, Stillwater Investment Management boosted its position in Amgen by 1.0% in the fourth quarter. Stillwater Investment Management now owns 14,978 shares of the medical research company’s stock valued at $2,431,000 after buying an additional 154 shares in the last quarter.

Several other equities research analysts have also commented on the stock. Wells Fargo restated a hold rating on shares of Amgen in a report on Friday, January 22nd. Credit Suisse assumed coverage on shares of Amgen in a report on Tuesday, January 19th. They issued an outperform rating and a $205.00 price target for the company. Vetr lowered shares of Amgen from a strong-buy rating to a buy rating and set a $171.02 price target for the company. in a report on Friday, January 15th. JPMorgan Chase & Co. restated a neutral rating on shares of Amgen in a report on Wednesday, January 13th. Finally, Jefferies Group restated a buy rating on shares of Amgen in a report on Saturday, January 9th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $186.30.

Amgen (NASDAQ:AMGN) traded up 0.01% on Friday, reaching $152.75. 4,602,164 shares of the company’s stock traded hands. Amgen has a 12-month low of $130.09 and a 12-month high of $181.81. The stock has a market cap of $115.17 billion and a price-to-earnings ratio of 16.86. The stock has a 50 day moving average price of $156.28 and a 200 day moving average price of $156.83.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, January 28th. The medical research company reported $2.61 EPS for the quarter, beating the consensus estimate of $2.29 by $0.32. During the same quarter in the prior year, the firm posted $2.16 EPS. The business earned $5.54 billion during the quarter, compared to the consensus estimate of $5.53 billion. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. Analysts forecast that Amgen will post $10.73 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 8th. Investors of record on Tuesday, February 16th will be paid a $1.00 dividend. This represents a $4.00 annualized dividend and a dividend yield of 2.62%. The ex-dividend date is Thursday, February 11th. This is an increase from Amgen’s previous quarterly dividend of $0.47.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.

12 Month Chart for NASDAQ:AMGN

Stock Target Prices

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.